INTRODUCTION
The upfront administration of preoperative chemotherapy is widely accepted as the standard treatment for large primary breast tumors and inflammatory breast cancer. This strategy is being increasingly used in operable disease too, mainly to increase the number of patients eligible for breastconserving surgery (1, 2) . Moreover, it allows to obtain important prognostic information by in vivo assessment of the treatment activity. In fact, achievement of a pathological complete response (pCR) is a strong predictor of long-term breast cancer outcome, independent of stage at diagnosis and molecular subtype (3) (4) (5) (6) . Several biological tumor features Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis Pathology All patients underwent needle biopsy of the breast tumor for histological diagnosis. All materials were fixed in 4% formaldehyde and embedded in paraffin. Sections were cut on a microtome and stained with hematoxylin and eosin. All pathological specimens were examined by dedicated breast pathologists. The following parameters were evaluated: histological tumor type, nuclear grade, estrogen receptor (ER), progesterone receptor (PgR), HER2, proliferation index (Ki-67), p53, and EGFR expression. Histological type was defined according to the World Health Organization classification. Histological grade was defined according to the Elston and Ellis grading system. ER, PgR, p53 and EGFR were determined by immunohistochemistry. All immunohistochemical analyses were performed using a streptavidin-biotin-peroxidase system in a Benchmark XT automated immunostainer (Ventana Medical Systems, Tucson, AZ, USA). Staining protocols for each antibody had been previously optimized and standardized for routine histopathological diagnosis. Briefly, 4-μm-thick tissue sections were cut from representative blocks and mounted on charged and precleaned slides. Sections were dewaxed in xylene and rehydrated through a decreasing concentration of alcohol to water. Heat-induced antigen retrieval (HIAR) (immersion in citrate buffer, pH 6.0, at 95°C for 30 minutes followed by cooling at room temperature for 20 minutes) or, alternatively, treatment with protease XIV for 10 minutes was applied. Subsequently, sections were incubated with 0.3% hydrogen peroxide in methanol for 30 minutes to block endogenous peroxidase activity. The monoclonal antibodies used in the study and their technical characteristics were the following: ER (Ventana Medical Systems, clone SP1, prediluted, HIAR); PgR (Ventana, clone 1E2, prediluted, HIAR); p53 (Ventana, clone D07, prediluted, HIAR); EGFR (Zymed, clone 31G, protease pretreatment, 1:100 dilution); Ki-67 (DAKO, clone Ki67-MIB-1, 1:200 dilution, HIAR). 3'-3diaminobenzidine was used as the chromogen, whereas counterstaining was obtained with 1% modified Harris hematoxylin. Controls for the specificity of staining were performed by immunostaining duplicate sections in the absence of the primary antibody within each batch of slides.
HER2 status was evaluated by immunohistochemistry (Ventana, MoAb HER2, clone 4B5, prediluted, HIAR) or by fluorescence in situ hybridization (FISH) (PathVysion). Samples were considered positive for HER2 in case of 3+ immunohistochemistry and/or gene amplification found on FISH testing, according to ASCO/CAP guidelines (26). Staining was assessed independently by 2 pathologists (GF, AM) with a standard light microscope. The relevant subcellular localization (nuclear for ER, PgR, p53, Ki-67; membranous for HER2; cytoplasmic and/or membranous for EGFR) and the percentage of positive neoplastic cells induced by various chemotherapeutic agents causes an increase in the level of TP53 gene, with subsequent G1 cell cycle arrest and activation of apoptosis. TP53 mutations are the most frequent genetic events in human cancer: in cells with altered TP53 function, proliferation is no longer under control, leading to deficiency in DNA repair and genetic instability (12, 13) . The predictive and prognostic role of TP53 in breast cancer patients receiving primary systemic therapy has been widely investigated, but the results have been inconsistent (14-24).
Cellular accumulation of p53 protein is a consequence of most of the mutations at the gene level and can be easily assessed by immunohistochemistry. Therefore, immunohistochemical staining for p53 has been adopted as a surrogate marker for TP53 mutation (25). The aim of this study was to evaluate the predictive and prognostic role of immunohistochemical determination of p53 in patients with different molecular subtypes of breast cancer treated with preoperative chemotherapy.
METHODS

Patients and treatment
Prospectively collected data from 154 breast cancer patients treated with preoperative chemotherapy for whom tissue of the diagnostic biopsy was available for analysis were evaluated. At diagnosis, patients underwent a complete staging workup including chest x-ray, abdominal ultrasonography, and bone scan in those patients who had clinically enlarged axillary lymph nodes. The local extent of disease was evaluated by mammography, breast ultrasonography, and clinically by caliper.
Clinical response was assessed by caliper at each chemotherapy course. At the completion of the preoperative chemotherapy plan, reevaluation of local disease extent was performed by mammography and breast ultrasonography. The eligibility for breast-conserving surgery was evaluated by a multidisciplinary team including radiologists, surgeons, reconstructive surgeons, and oncologists. After surgery, radiation therapy was recommended in the following cases: breast-conserving surgery, primary tumor size before chemotherapy >5 cm, and ≥4 involved axillary nodes after preoperative chemotherapy. Adjuvant hormonal therapy was administered in case of hormone receptor (HR)-positive tumors: premenopausal patients received tamoxifen +/-LH-RH agonists; postmenopausal patients received either tamoxifen or aromatase inhibitors. Regular follow-up including clinical examination, complete blood chemistry, CEA and CA 15-3 measurement, chest x-ray, liver ultrasound, and mammography was performed up to 5 years. After 5 years, patients were followed yearly with clinical examination, complete blood chemistry, CEA and CA 15-3 measurement, and mammography. patients (5.2%) were in pCR and 94 patients (61%) had involved axillary lymph nodes.
p53 and tumor biology p53 was expressed in 43.5% of the tumors (mean p53 expression 24.5%, range 0-99%). A significant association between p53 and molecular subtypes, tumor differentiation, and cell proliferation was observed. In particular, p53 expression was more frequent in triplenegative than in HR-positive patients (odds ratio [OR] 2.45, 95% confidence interval [CI] 1.03-5.82, p=0.041). A trend towards higher p53 expression was observed in the HER2-positive group (OR 2.21, 95%CI 0.98-4.96, p=0.054). The OR for p53 expression was 2.67 in nuclear grade 3 tumors versus grade 1 and 2 (95%CI 1.31-5.41, p=0.006), and 2.79 in tumors with high proliferation (Ki-67 ≥15%) versus tumors with low proliferation (95%CI 1.20-6.46, p=0.017). No association between p53 and EGFR was observed.
in 10 consecutive high-power fields were recorded. p53 was considered overexpressed when at least 10% of tumor cell nuclei stained positively. The Ki-67 proliferation index was derived and a cutoff value of 15% was chosen to discriminate between tumors with high proliferation (Ki-67 ≥15%) and tumors with low proliferation (Ki-67 <15%) tumors. The cutoff value of 10% for p53, although arbitrarily chosen, is frequently reported in the literature (14, 17, 18) .
Assessment of response
pCR was defined as complete disappearance of invasive carcinoma in the breast and axillary lymph nodes. Residual ductal carcinoma in situ was included in the pCR category.
Statistical analysis
The association between biomarker expression and pCR was assessed by logistic regression analysis. Survival curves were estimated with the Kaplan-Meier method and the log-rank test was used to test for differences between groups. Disease-free survival (DFS) was calculated from the date of surgery to the date of disease relapse (local or distant), death from any cause, or last follow-up. Overall survival (OS) was calculated from the date of diagnosis to the date of death or last follow-up. Hazard ratios and their confidence intervals were estimated with the Cox model. Results were considered statistically significant when p was <0.05.
RESULTS
Patients and response
One-hundred fifty-four patients were eligible for the study; their characteristics are listed in Table I . On the basis of hormone receptor and HER2 status, the tumors were classified into 3 molecular subtypes: triple negative (28 patients, 18.2%), HR positive (93 patients, 60.4%), and HER2 positive (33 patients, 21.4%). The triplenegative subtype included patients with negative HER2 and negative hormone receptors as defined as complete absence of ER or PgR, with the other receptor expressed at less than 5%. The HR-positive group included patients with positive HR and negative HER2. The HER2-positive group included patients with positive HER2, regardless of HR expression. Preoperative chemotherapy consisted of anthracycline-taxane combination chemotherapy in 73% and anthracycline-based chemotherapy in 27% of the patients.
After a median of 4 preoperative chemotherapy courses (range 1-8), all patients underwent surgery: 45% breast-conserving surgery and 55% mastectomy. Eight 
Survival analyses
In the overall patient series, the 5-year DFS and OS were 71% and 86%, respectively. In univariate analysis, expression of p53, together with high proliferation and lymph node involvement after preoperative chemotherapy, were predictors of a worse DFS. Patients with p53 positivity also had a worse OS. In particular, the 5-year DFS was 56% in patients with p53 expression and 82% in non-p53-expressing patients (log-rank test p=0.004); the 5-year OS was 69% and 99% in the 2 groups, respectively (log-rank test p=0.0002) ( Figs. 1 and 2) . When grouping patients according to molecular subtypes, the probability of relapse was not significantly different among the 3 groups; however, both the triple-negative and HER2positive subgroups had a significantly worse OS than the Prediction of pathological complete response p53 expression, molecular subtype, and nuclear grading were found to be significant predictors of the probability of pCR. The OR for pCR in p53-expressing patients was 10.03 compared to patients without p53 expression (p=0.0077). The triple-negative and HER2positive subgroups were more likely to achieve a pCR than the HR-positive group (OR 10.8 and 12.41 with p=0.043 and p=0.027, respectively). In poorly differentiated tumors, the OR for pCR was 7.25 as compared to well or moderately differentiated tumors (p=0.0389). No association between EGFR or proliferation and pCR was observed (Tab. II). relation between tumor biomarkers and the achievement of pCR is easily and immediately assessable. By contrast, a long follow-up is needed in the adjuvant, postoperative setting; moreover, the identification of predictive factors is made more difficult because most tumor biomarkers play a predictive as well as prognostic role. The absence of hormone receptors, poor differentiation, a high proliferation rate, and HER2 expression are recognized as predictors of the likelihood of pCR after preoperative therapy. However, HER2 is the only factor routinely used to select patients for treatment with trastuzumab-based regimens, while all the other factors can be considered predictors of chemosensitivity as well as markers of tumor aggressiveness. Nevertheless, their prognostic impact in those patients who do not achieve a pCR is still under evaluation.
On these premises, p53 can be a good marker of responsiveness to specific chemotherapeutic agents and HR-positive, HER2-negative group (5-year OS 79% and 81% vs 90%, respectively; log-rank test p=0.04) (Tab. III).
In multivariate analysis, after adjustment for molecular subtypes and proliferation, both p53 expression and nodal status after preoperative chemotherapy were significant predictors of DFS and OS. The hazard ratios (HRs) for relapse and death in p53-expressing versus non-p53-expressing patients were 2.29 (p=0.015) and 7.74 (p=0.002), respectively. The HRs for relapse and death in node-positive versus node-negative patients were 3.63 (p=0.003) and 3.64 (p=0.041), respectively (Tab. IV).
DISCUSSION
Preoperative chemotherapy allows to evaluate the sensitivity to treatment and to discriminate the predictive and prognostic value of multiple parameters. In fact, the in techniques and patient populations. Several studies have described an association of p53 expression with hormone receptor negativity, high proliferation rate, high histological and nuclear grades, aneuploidy, and poorer outcome (36). More recently, an association between high p53 levels and HER2 positivity has been reported (37). However, in a meta-analysis of more than 9000 patients, the predictive and prognostic role of the immunohistochemical detection of p53 was found to be weak (38).
In the univariate analysis of our study, we found a strong correlation between p53 expression status and worse DFS and OS. High proliferation and lymph node involvement after preoperative chemotherapy were also significantly associated with a worse DFS. Interestingly, no differences in terms of DFS were found according to the different molecular subtypes, while in terms of OS both the triple-negative and HER2-positive subgroups had a significantly worse outcome as compared to patients with HR-positive, HER2-negative disease. These findings might reflect the different natural history and different treatment availability for each molecular subtype, with hormone-sensitive disease usually being associated with nonvisceral metastases and prolonged survival. In multivariate analysis, when including molecular subtypes, proliferation rate, p53 expression, and nodal status, only p53 expression and nodal positivity remained significant predictors of both DFS and OS. Therefore, in this series of patients, p53 expression was an independent prognostic factor. These results are consistent with those described when evaluating TP53 by molecular analysis. In fact, the strong prognostic significance of TP53 mutations has been confirmed by a meta-analysis including over 3500 patients (39) .
It has been shown that there are "null mutations" in the TP53 gene that do not lead to protein accumulation, which means that immunohistochemistry might remain negative and this might partly account for the greater consistency of molecular analyses. However, although the reproducibility of semiquantitative immunohistochemical biomarker determination can be a critical issue, the validation of immunohistochemistry is fundamental to allow for the clinical application of prognostic factors: in fact, gene sequencing is generally time and resource consuming and cannot be routinely performed in daily clinical practice.
In summary, in our series, immunohistochemical p53 expression was consistently associated with hormone receptor negativity, poor differentiation, and high proliferation, as already described in the literature. p53 was a significant predictor of pCR following anthracycline-and taxane-based regimens, and, after adjustment for molecular subtype and cell proliferation, was an independent predictor of a worse DFS and OS.
On the basis of these results, we believe that the could play a prognostic role in patients not achieving a pCR. The primary aim of this study was to evaluate the predictive role of p53, in particular its relation with pCR. In our analysis, p53 expression was significantly associated with markers of aggressive tumor biology, such as triple-negative tumor phenotype, high proliferation, and poor differentiation, which are all markers of higher chemosensitivity. Indeed, we found a significant association between the achievement of pCR and p53 expression, HER2-positive and triple-negative molecular subtypes, and nuclear grade 3.
The ability of p53 to predict the efficacy of neoadjuvant chemotherapy is still a matter of controversy. Since most anticancer agents act by inducing apoptosis (27, 28) , defects in regulators of apoptosis have been implicated in chemoresistance. There is evidence from in vitro and animal studies that p53 deficiency is associated with chemoresistance (29, 30) . Several neoadjuvant studies have failed to find a consistent association between p53 and responsiveness to chemotherapy. However, the lack of consistency is not surprising in view of the heterogeneity not only in p53 status assessment, but mostly taking into account the differences in patient populations and chemotherapy regimens across studies. It has been shown that p53-positive tumors responded poorly to anthracyclines and/or alkylating agents, while p53-deficient tumors responded better to taxanes (31-35). In our analysis, the association of p53 expression with a higher likelihood of pCR is consistent if we consider its relation to tumor biology. In fact, as previously stated, the probability of pCR is higher in cases of HER2 positivity, absence of hormone receptors, high tumor grade, and high proliferation rate. In the multivariate analysis of our study, all the significant factors in univariate analyses were no longer significantly associated with the odds of pCR (data not shown). Therefore, we must acknowledge that the effect of p53 alteration on chemosensitivity might partly be linked to the other markers of chemosensitivity, but the precise role of each parameter cannot be estimated. Intriguingly, all patients attaining a pCR in this study received a combination of anthracyclines and taxanes; however, the small number of patients in pCR does not allow us to speculate on the role of p53 in predicting the response to taxanes.
The other main objective of the present analysis was to evaluate the association between p53 expression and survival. It is universally recognized that, on the basis of HR and HER2 expression, there are at least 3 different breast cancer subtypes with distinct biological features, clinical course and sensitivity to treatment: hormone receptor positive, triple negative, and HER2 positive. We have therefore investigated the prognostic role of p53 expression taking into account these 3 subtypes.
The prognostic role of immunohistochemical detection of p53 is controversial, largely because of heterogeneity
